Department of Orthopaedic Surgery

Bing Wang, MD, PhD

  • Associate Professor
  • Director, Molecular Therapeutics Laboratory

Dr. Bing Wang works as an associate professor and the director of the Molecular Therapy Laboratory in the Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine. Dr. Wang received his MD degree in 1986 from Tong-Ji Medical School, Huazhong University of Science and Technology, and Ph.D. degree in 1998 from the Chinese Academy of Science. Before joining the University of Pittsburgh in 1999, he held an associate professor in the Chinese Academy of Science.

Dr. Wang was elected to the Nominating Committee of the Orthopaedic Research Society for a 2013–2014 term. He also continues to serve as a committee member of the American Society of Gene and Cell Therapy--The Musculoskeletal Gene & Cell Therapy--for another term, 2013 to 2016.

Education & Training

  • MD, Tongji Medical School, Huazhong University of Science and Technology
  • PhD, Chinese Academy of Science

Representative Publications

Role of angiogenesis in tissue regeneration

  1. Sarah Beckman, et al. The beneficial effect of mechanical stimulation on the regenerative potential of MDSCs is lost by inhibiting VEGF. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013; 3(33):2004-2012.
  2. Koji Takayama. The effect of blocking angiogenesis on anterior cruciate ligament healing following stem cell transplantation. Biomaterials, 2015, 60:9-19.

Viral-based engineering stem cells for tissue regeneration

  1. Michael Y. Mi, et al. AAV based ex vivo gene therapy in rabbit adipose-derived mesenchymal stem/progenitor cells for osteogenesis. The Open Stem Cell Journal, 2009,1:69-75. 
  2. Xueqin Gao, et al. A comparison of bone regeneration with human mesenchymal stemcells and muscle-derived stem cells and the critical role of BMP. Biomaterials 2014, 35:6859-6870.

Development of recombinant adeno-associated viral (rAAV) vectors

  1. Zhong Wang, et al. Adeno-associated Virus Serotype 8 Efficiently Delivers Genes to Muscle and Heart. Nat Biotechnol. 2005, 23(3):321-328. PMID: 15735640.
  2. Bing Wang, et al.  Construction and analysis of compact muscle-specific promoters forAAV Vectors. Gene Therapy, 2008, 15 (22):1489-1499. PMID: 18563184. (Corresponding Author).

AAV-based gene replacement for musculoskeletal diseases

  1. Bing Wang, et al. Adeno-associated Virus Vector Carrying Human Minidystrophin Genes Effectively Ameliorates Muscular Dystrophy in mdx Mouse Model Proc. Natl. Acad. Sci.USA., 2000, 97(25): 13714-13719. PMID: 11095710.
  2. Bing Wang, et al. Systemic human minidystrophin gene transfer improves functions and life-span of dystrophin and dystrophin/utrophin deficient mice. Journal of Orthopaedic Research, 2009, 27 (4):421-426. PMID: 18973234. (Corresponding Author).

Anti-inflammation in musculoskeletal system through blocking NF-κB pathway

  1. Ying Tang, et al. Inhibition of the IKK/NF-κB Pathway by AAV Gene Transfer Improves Muscle Regeneration in Older mdx Mice. Gene Therapy, 2010, 17 (12), 1476-1483, PMID:20720575.
  2. Qing Yang, et al. AAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice. Gene Therapy, 2012, 19:1196-1204, PMID: 22278411
  3. Aiping Lu, et al. NF-κB Negatively Impacts the Myogenic Potential of Muscle-derived Stem Cells. Molecular Therapy, 2012, 20 (3): 661-668. PMID: 22158056.

Research Interests

Dr. Wang has been engaging in viral vector-mediated gene transfer and associated techniques.These therapeutic strategies represent the most promising approaches to aid in the repair andregeneration of muscle, bone, ligament, tendon, and joint capsules. He has laid the groundworkfor the researches by developing gene- and cell-based molecular techniques for in vivo and exvivo gene transfer as well as biomaterial-mediated gene transfer for the treatment ofmusculoskeletal diseases, including gene therapy for DMD treatment and gene-activatedbiomaterials for tissue repair. He also actively engaged in clinical applications of gene and celltherapies combined with tissue engineering through collaboration with many laboratoriesinternal and external to the University of Pittsburgh. Dr. Wang has supervised and co-supervised postdoctoral fellows, resident follows and graduate students.

Research Grants

1. Title: Role of Omega (ω)-3 Polyunsaturated Fatty Acids in Duchenne Muscular Dystrophy
Performance Period: 07/01/2014 – 06/30/2016 (NCE)
Supporting Agency: The Pittsburgh Foundation
Role: PI
Level of Funding: $5,000

2. Title: Gene-activated Microfibrous Scaffold for Tendon/Ligament Soft Tissue Reconstruction
Performance Period: 07/01/2015 – 06/30/2016
Role: PI
Supporting Agency: The Pittsburgh Foundation
Level of Funding: $5,000

3. Title: The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeletal Tissue Repair
Performance Period: 04/04/2014 – 03/31/2016
Role: Co-I
Supporting Agency: National Institutes of Health
Level of Funding: $372,268

4. Title: Bone Abnormalities & Healing Defect in Muscular Dystrophy
Performance Period: 05/06/2014 – 04/30/2019
Role: Co-I
Supporting Agency: National Institutes of Health
Level of Funding: $1,693,175